目的 分析哌拉西林他唑巴坦對支氣管擴張患者肺功能、血沉（ESR）、C反應蛋白（CRP）水平的影響及療效。方法 回顧性選取2015年7月-2017年8月馬鞍山市中心醫(yī)院收治的支氣管擴張患者124例，根據(jù)治療方法不同分為對照組和觀察組。對照組患者采用常規(guī)治療，觀察組患者采用常規(guī)治療聯(lián)合哌拉西林他唑巴坦治療，均連續(xù)治療10 d。觀察兩組患者治療前后發(fā)熱、咳嗽咯痰、肺部濕啰音、肺部炎癥緩解時間、痰液性質(zhì)、肺功能指標、ESR、CRP水平變化情況。結(jié)果 觀察組患者發(fā)熱、咳嗽咯痰、肺部濕啰音、肺部炎癥緩解時間均顯著短于對照組，差異有統(tǒng)計學意義（P<0.05）。治療前，兩組患者痰液性質(zhì)情況比較無統(tǒng)計學差異。治療后，觀察組患者黏液體積評分顯著高于對照組，黏液密度、膿性黏液評分顯著低于對照組，差異均有統(tǒng)計學意義（P<0.05）。治療前，兩組患者ESR、CRP水平比較無統(tǒng)計學差異。治療后，觀察組患者ESR、CRP水平均顯著低于對照組（P<0.05）。治療前，兩組患者肺功能指標水平比較無統(tǒng)計學差異。治療后，觀察組患者FVC、FEV1水平均顯著高于對照組（P<0.05）。結(jié)論 哌拉西林他唑巴坦治療支氣管擴張可改善患者痰液性質(zhì)和肺功能，快速緩解臨床癥狀，抑制患者ESR、CRP的表達。

Objective To analyze the effect and effect of piperacillin tazobactam on bronchiectasis, ESR, CRP level.Methods Review from July 2015 to August 2017 in our hospital 124 cases of patients with bronchiectasis, according to the different treatment methods were divided into control group and observation group. The control group was treated with conventional treatment, the observation group were treated by routine treatment combined with piperacillin tazobactam in the treatment, analysis of the clinical effect of two groups of patients after treatment.Results The observation group of patients with fever, cough, expectoration, pulmonary rales, lung inflammation remission time were shorter than the control group (P < 0.05). Before treatment, no significant differences between the two groups of patients with sputum properties. After treatment, the volume of patients observed mucus scores higher than the control group, the density of mucus, purulent mucus score below the control group (P < 0.05). The two groups of patients before treatment, ESR, CRP beta, no significant differences between the levels of CRP. After the treatment, the patients in the observation group were ESR, CRP water was lower than that of the control group (P < 0.05). Before treatment, there was no significant difference in the level of pulmonary function between the two groups. After treatment, the levels of FVC and FEV1 in the observation group were all higher than those in the control group (P < 0.05).Conclusion Piperacillin tazobactam in the treatment of bronchiectasis can improve the nature of sputum and lung function, quickly relieve the clinical symptoms, and inhibit the expression of ESR and CRP.